Moderna Inventory Energetic On Q1 Earnings Beat, Vaccine Gross sales Forecast

[ad_1]

Up to date at 10:56 am EST

Moderna  (MRNA) – Get Moderna, Inc. Report shares surged greater Wednesday after the drugmaker posted a lot stronger-than-expected first quarter earnings whereas re-affirming its full-year forecast for Covid vaccine gross sales.

Moderna posted diluted GAAP earnings of $8.58 per share for the three months ending in March, up greater than three-fold from the identical interval final 12 months and nicely forward of the Avenue consensus forecast of $5.21 per share. Group revenues additionally firmly topped analysts’ estimates, coming in at $6.1 billion. Round 975 of that tally got here from Covid vaccine gross sales.



[ad_2]
Source link